
Relmada Therapeutics fell 28.0% from $4.32 to $3.11, behind the S&P 500's +5.7%. Its worst day was Nov 17 (−16.6%), and its low came Nov 18 at $2.86.
Nov 20, 2025 – Nov 19, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Durable 76% complete response (CR) rate at 12 months with 95% CR rate at any time in high-risk NMIBCBCG-unresponsive patients achieved an 80% CR rate at 12 months and 94% CR rate at any timeTolerability profile remains
+61.1%, the year's best day, on 43M shares, the year's heaviest volume · S&P 500 +0.9%
Story events cover the past 12 months · Times ET
EPS of $-0.27 missed the $-0.14 estimate on $0.00 revenue.
−2.9% · S&P 500 −1.4%
EPS of $-0.22 missed the $-0.19 estimate on $0.00 revenue.
+0.5% · S&P 500 +0.6%
EPS of $-0.11 beat the $-0.20 estimate on $0.00 revenue.
−8.0% · S&P 500 +0.6%
EPS of $-0.12 beat the $-0.14 estimate on $0.00 revenue.
+1.2% · S&P 500 −0.4%
Where it ended: a close of $3.11 on Nov 19, 2026. Up next: Q4 2026 earnings on Mar 18, 2027 (EPS est. $-0.12).
Nothing in the past 12 months.
All RLMD dividend historyReplay the year: the line draws itself and stops at each of the 5 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for RLMD and SPY from Benzinga historical bars. Not investment advice.